3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Osteosarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Liposarcoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
trifluridine tipiracil drug combination
1
trametinib
1
regorafenib
1
milademetan
1
larotrectinib
1
futibatinib
1
dabrafenib
1
brigimadlin
1
apixaban
1
TAS-116
1
Rivaroxaban
1
Ramucirumab
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Nivolumab
1
Gemcitabine
1
Fluorouracil
1
Dalteparin
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
4-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Clinical Trials, Phase II as Topic
×
Sarcoma
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled